Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Enveric Biosciences IncTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Oxford Lane Capital Corp — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Oxford Lane Capital Corp trades at $9.34 (market cap $905.21M). The key difference: Oxford Lane Capital Corp is far larger — about 146× Enveric Biosciences Inc's market cap, and Oxford Lane Capital Corp pays a 25.89% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBOXLC
Market Cap
$6.20M$905.21M
Sector
HealthFinancials
52-Week High
$17.40$18.75
52-Week Low
$1.27$8.15
Enterprise Value
$1.30M
Dividend Yield
25.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Oxford Lane Capital Corp

OXLC trades at $9.20, up 0.44% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock's valuation shows a low price-to-book ratio of 0.88, yet profitability metrics are deeply negative with an ROE of -39.16%. Recent earnings have consistently missed expectations, and the company has declared a series of $0.20 dividends through 2026. Cash flow from operations was negative $703.80M in 2025, offset by financing activities.

The outlook is clouded by severe fundamental deterioration, including a projected revenue collapse and net loss for 2026. While the high dividend yield and discounted P/B may attract some investors, the risks from unsustainable distributions, declining net asset value, and negative returns on equity warrant extreme caution. Analyst sentiment is mixed, reflecting the stock's high-risk, high-yield profile.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC